Skip to content

Clinical research of atorvastatin to evaluate the effect of OATP2B1 inhibition

Clinical research of atorvastatin to evaluate the effect of OATP2B1 inhibition - Atorvastatin-drug interaction through inhibition of OATP2B1

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000005864
Enrollment
16
Registered
2011-06-28
Start date
2011-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy male

Interventions

celiprolol and atorvastatin, wash out, fexofenadine and atorvastatin fexofenadine and atorvastatin, wash out, celiprolol and atorvastatin

Sponsors

Department of clinical pharmacokinetics, Kyushu University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: the investigors must ensure that all subjects being considerd meet the following inclusion criteria: 1) Japanese healthy male who is capable to understand and sign the informed consent. 2) 20-45 years of age 3)BMI 18.5-25.0 4)good health as determined by physical examination, vital signs and laboartory tests.

Exclusion criteria

Exclusion criteria: the investigors must ensure that all subjects being considerd meet the following exclusion criteria or conditions: 1)history of allergy to any drugs 2)medical attention within 2 months prior to participation 3)donation of 200mL or more of blood within 4 weeks prior to participation, or donation of component blood within 2 weeks prior to participation 4)donation of 400mL or more of blood within 12 weeks prior to participation 5)recent (past 4 months) participation in other clinical trial for investigational new chemical entity 6)history of drug abuse 7)alcohol abuse

Design outcomes

Primary

MeasureTime frame
PK profiles of celiprolol, fexofenadine and atorvastatin

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026